US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Contineum Therapeutics, INC.

8.65

+0.08500.99%

Volume:1.70M

Turnover:14.47M

Market Cap:325.42M

PE:-5.03

High:8.94

Open:8.50

Low:8.10

Close:8.57

52wk High:17.79

52wk Low:8.10

Shares:37.62M

Float Shares:31.54M

Volume Ratio:0.93

T/O Rate:5.40%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.7201

EPS(LYR):-2.1700

ROE:-28.01%

ROA:-19.15%

PB:1.36

PE(LYR):-3.99

Loading ...

Overview Company News Filings

Contineum price target lowered to $19 from $20 at Baird

Contineum Therapeutics, Inc. : Leerink Partners Cuts Target Price to $22 from $25

THOMSON REUTERS

Stocks to Watch: Dave & Buster's, Contineum, Boxlight, Kestra Medical

Analyst Maintains Buy on Contineum, Trims Price Target to $23 Following PIPE-307 Setback While PIPE-791 IPF Program Remains Core Value Driver

Analyst Reaffirms Buy on Contineum, Highlighting PIPE-791 IPF Upside Despite Muscarinic MDD Trial Setback

Contineum Therapeutics Says Phase 2 Major Depressive Disorder Study Fails to Meet Primary Efficacy Endpoint

MT Newswires Live

Contineum Therapeutics Shares Fall After Drug Trial Missed Primary Endpoint

Contineum Therapeutics Reports Phase 2 MOONLIGHT-1 Results

Contineum, J&J's Depression Drug Fails to Meet Mid-Stage Trial Goal

Contineum says MOONLIGHT-1 trial did not achieve its primary endpoint

Contineum down 11% atter MOONLIGHT-1 trial did not achieve endpoint

Contineum Therapeutics, - Jnj-5120/Pipe-307 Well-Tolerated with no New Safety Signals

THOMSON REUTERS

Contineum Therapeutics, - Analyses of Data Including Exploratory Endpoints are Ongoing

THOMSON REUTERS

Contineum Therapeutics Reports Phase 2 Results for Jnj-5120/Pipe-307 for the Treatment of Major Depressive Disorder

THOMSON REUTERS

Contineum Therapeutics, - Phase 2 Moonlight-1 Trial Did not Meet Primary Efficacy Endpoint

THOMSON REUTERS

Contineum Therapeutics, - Johnson & Johnson Continues to Evaluate Trial Data for Jnj-5120/Pipe-307

THOMSON REUTERS

Contineum Therapeutics CEO Carmine N. Stengone Disposes of 2,500 Common Shares for $41,141.5

Contineum Therapeutics, Inc. Class A (CTNM) Receives a Buy from RBC Capital

Contineum Therapeutics to Present at Morgan Stanley Global Healthcare Conference

Contineum, Disc Medicine, Recursion Advance Pipelines Ahead of Catalysts, Morgan Stanley Says

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigermarketb.com/stock/CTNM/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CTNM","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CTNM\",,,,,undefined,":{"symbol":"CTNM","market":"US","secType":"STK","nameCN":"Contineum Therapeutics, INC.","latestPrice":8.65,"timestamp":1791915937633,"preClose":8.565,"halted":0,"volume":1703310,"delay":0,"changeRate":0.009924109748978501,"floatShares":31541528,"shares":37621100,"eps":-1.720127,"marketStatus":"Trading","change":0.085,"latestTime":"10-13 14:25:39 EDT","open":8.5,"high":8.94,"low":8.095,"amount":14466860.79111,"amplitude":0.098657,"askPrice":8.66,"askSize":215,"bidPrice":8.64,"bidSize":302,"shortable":0,"etf":0,"ttmEps":-1.720127,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1791921600000},"marketStatusCode":2,"adr":0,"listingDate":1712289600000,"exchange":"NASDAQ","adjPreClose":8.565,"preHourTrading":{"tag":"盘前","latestPrice":8.56,"preClose":8.565,"latestTime":"09:29 EDT","volume":16504,"amount":142017.25008,"timestamp":1791898199999,"change":-0.005,"changeRate":-0.000584,"amplitude":0.052563},"postHourTrading":{"tag":"盘后","latestPrice":8.65,"preClose":8.565,"latestTime":"19:59 EDT","volume":52757,"amount":463802.3535,"timestamp":1791849559115,"change":0.085,"changeRate":0.009924,"amplitude":0.050788},"volumeRatio":0.934979,"optionData":{"bulkOrders":[{"symbol":"CTNM","call":false,"expireDate":1799989200000,"strike":"15.0","timestamp":1791900183523,"price":6.54,"volume":1750,"amount":1144500,"type":"-"},{"symbol":"CTNM","call":false,"expireDate":1799989200000,"strike":"10.0","timestamp":1791900183523,"price":2.69,"volume":1750,"amount":470750,"type":"+"}]},"impliedVol":1.1495,"impliedVolPercentile":0.6215},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CTNM\",,,,,undefined,":{"symbol":"CTNM","floatShares":31541528,"roa":"-19.15%","roe":"-28.01%","lyrEps":-2.169999,"volumeRatio":0.934979,"shares":37621100,"dividePrice":0,"high":8.94,"amplitude":0.098657,"preClose":8.565,"low":8.095,"week52Low":8.095,"pbRate":"1.36","week52High":17.785,"institutionHeld":0,"latestPrice":8.65,"committee":0.168279,"eps":-1.720127,"divideRate":0,"volume":1703310,"delay":0,"ttmEps":-1.720127,"open":8.5,"prevYearClose":11.43,"prevWeekClose":13.38,"prevMonthClose":13.42,"prevQuarterClose":13.42,"fiveDayClose":12.65,"twentyDayClose":13.82,"sixtyDayClose":13.53},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CTNM\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-07-30","symbol":"CTNM","fiscalQuarterEnding":"2026/06","expectedEps":-0.46,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1785384000000,"reportTimeType":"post","actualEps":-0.4},{"market":"US","date":"2026-05-05","symbol":"CTNM","fiscalQuarterEnding":"2026/03","expectedEps":-0.55,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1777953600000,"reportTimeType":"post","actualEps":-0.39},{"market":"US","date":"2026-03-05","symbol":"CTNM","fiscalQuarterEnding":"2025/12","expectedEps":-0.5,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1772686800000,"reportTimeType":"post","actualEps":-0.49},{"market":"US","date":"2025-10-30","symbol":"CTNM","fiscalQuarterEnding":"2025/09","expectedEps":-0.58,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1761796800000,"reportTimeType":"post","actualEps":-0.45},{"market":"US","date":"2025-08-05","symbol":"CTNM","fiscalQuarterEnding":"2025/06","expectedEps":-0.56,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1754366400000,"reportTimeType":"post","actualEps":-0.62}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CTNM\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CTNM\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.375,"hold":0.125,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.375,"analysts":8,"updateTime":1785729600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CTNM\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CTNM","date":"2026-10-12","current":-5.028698,"percent":0.331699,"low":-16.425726,"twenty":-9.890815,"median":-6.704683,"eighty":-2.447689,"high":28.322904,"avg":-4.264865,"sd":9.816128,"marketCap":503370746},"quantilePoints":[{"date":"2024-04-05","current":16.281367,"twenty":16.281367,"median":16.281367,"eighty":16.281367,"marketCap":369912656},{"date":"2024-04-12","current":17.609251,"twenty":16.281367,"median":16.569509,"eighty":16.868158,"marketCap":400082176},{"date":"2024-04-19","current":17.122563,"twenty":16.281367,"median":16.868158,"eighty":17.144685,"marketCap":389024629},{"date":"2024-04-26","current":17.686678,"twenty":16.315104,"median":17.089379,"eighty":17.59819,"marketCap":401841332},{"date":"2024-05-03","current":16.48102,"twenty":16.48102,"median":17.122563,"eighty":17.59819,"marketCap":374448771},{"date":"2024-05-10","current":17.719862,"twenty":16.38147,"median":17.105971,"eighty":17.59819,"marketCap":402595255},{"date":"2024-05-17","current":16.547386,"twenty":16.392531,"median":17.100441,"eighty":17.487579,"marketCap":375956618},{"date":"2024-05-24","current":17.819411,"twenty":16.48102,"median":17.133624,"eighty":17.59819,"marketCap":404857026},{"date":"2024-05-31","current":20.173009,"twenty":16.534113,"median":17.172337,"eighty":17.68889,"marketCap":385849140},{"date":"2024-06-07","current":21.67926,"twenty":16.768608,"median":17.354846,"eighty":18.209439,"marketCap":414659209},{"date":"2024-06-14","current":22.311348,"twenty":16.85046,"median":17.388029,"eighty":20.619504,"marketCap":426749148},{"date":"2024-06-21","current":26.466988,"twenty":16.894704,"median":17.487579,"eighty":21.17897,"marketCap":506234071},{"date":"2024-06-28","current":25.216261,"twenty":16.921251,"median":17.542884,"eighty":21.517876,"marketCap":482311425},{"date":"2024-07-05","current":27.018383,"twenty":16.987617,"median":17.609251,"eighty":21.78147,"marketCap":516780614},{"date":"2024-07-12","current":28.242212,"twenty":17.042923,"median":17.692208,"eighty":22.916538,"marketCap":540188796},{"date":"2024-07-15","current":27.932893,"twenty":17.049559,"median":17.697739,"eighty":23.766494,"marketCap":534272442},{"date":"2024-08-02","current":26.224911,"twenty":17.056196,"median":17.697739,"eighty":24.100021,"marketCap":501603882},{"date":"2024-08-09","current":22.338245,"twenty":17.08938,"median":17.819411,"eighty":24.409341,"marketCap":427263614},{"date":"2024-08-16","current":-15.206885,"twenty":17.023013,"median":17.769636,"eighty":24.100021,"marketCap":478195700},{"date":"2024-08-23","current":-14.92058,"twenty":16.547386,"median":17.697739,"eighty":23.683112,"marketCap":469192554},{"date":"2024-08-30","current":-15.468649,"twenty":16.315104,"median":17.614781,"eighty":23.293101,"marketCap":486427149},{"date":"2024-09-06","current":-14.511573,"twenty":15.417858,"median":17.570537,"eighty":22.830467,"marketCap":456330916},{"date":"2024-09-13","current":-14.765157,"twenty":-14.025672,"median":17.410151,"eighty":22.682531,"marketCap":464305131},{"date":"2024-09-20","current":-16.425726,"twenty":-14.408503,"median":17.365907,"eighty":22.459283,"marketCap":516523382},{"date":"2024-09-27","current":-15.272326,"twenty":-14.745525,"median":17.19999,"eighty":22.405488,"marketCap":480253562},{"date":"2024-10-04","current":-14.421591,"twenty":-14.887859,"median":17.133624,"eighty":22.351694,"marketCap":453501355},{"date":"2024-10-11","current":-13.521775,"twenty":-14.788061,"median":17.100441,"eighty":22.316727,"marketCap":425205752},{"date":"2024-10-18","current":-13.480875,"twenty":-14.745525,"median":17.039604,"eighty":22.010098,"marketCap":423919588},{"date":"2024-10-25","current":-13.309092,"twenty":-14.662087,"median":16.868158,"eighty":21.934785,"marketCap":418517700},{"date":"2024-10-31","current":-14.004404,"twenty":-14.595828,"median":16.547386,"eighty":21.78147,"marketCap":440382485},{"date":"2024-11-08","current":-13.455721,"twenty":-14.532841,"median":16.387,"eighty":21.655052,"marketCap":477166769},{"date":"2024-11-15","current":-13.193473,"twenty":-14.477216,"median":16.281367,"eighty":21.566291,"marketCap":467866942},{"date":"2024-11-22","current":-10.423934,"twenty":-14.434679,"median":15.167037,"eighty":21.517876,"marketCap":369653551},{"date":"2024-11-29","current":-10.838275,"twenty":-14.411775,"median":-9.795154,"eighty":21.388769,"marketCap":384346893},{"date":"2024-12-06","current":-10.358512,"twenty":-14.347406,"median":-10.271282,"eighty":21.17897,"marketCap":367333550},{"date":"2024-12-13","current":-10.031401,"twenty":-14.270231,"median":-10.358512,"eighty":21.154762,"marketCap":355733543},{"date":"2024-12-20","current":-9.70429,"twenty":-14.217087,"median":-10.242206,"eighty":20.950342,"marketCap":344133536},{"date":"2024-12-27","current":-10.569317,"twenty":-14.14183,"median":-10.271282,"eighty":20.635643,"marketCap":374809110},{"date":"2025-01-03","current":-10.525702,"twenty":-14.135286,"median":-10.358512,"eighty":20.603366,"marketCap":373262442},{"date":"2025-01-10","current":-9.718828,"twenty":-14.073857,"median":-10.358512,"eighty":20.25908,"marketCap":344649092},{"date":"2025-01-17","current":-9.071876,"twenty":-14.047944,"median":-10.256744,"eighty":19.850241,"marketCap":321706856},{"date":"2025-01-24","current":-8.19958,"twenty":-14.045305,"median":-10.209494,"eighty":18.599466,"marketCap":290773505},{"date":"2025-01-31","current":-7.429052,"twenty":-14.035488,"median":-10.009594,"eighty":17.759682,"marketCap":263449044},{"date":"2025-02-07","current":-6.883867,"twenty":-14.024036,"median":-9.925999,"eighty":17.706588,"marketCap":244115699},{"date":"2025-02-14","current":-5.589962,"twenty":-14.010948,"median":-9.718828,"eighty":17.697739,"marketCap":198231228},{"date":"2025-02-21","current":-5.742614,"twenty":-13.988044,"median":-9.667944,"eighty":17.693315,"marketCap":203644564},{"date":"2025-02-28","current":-5.19016,"twenty":-13.940599,"median":-9.518928,"eighty":17.660132,"marketCap":184053442},{"date":"2025-03-07","current":-3.942751,"twenty":-13.847345,"median":-9.071876,"eighty":17.615888,"marketCap":166612775},{"date":"2025-03-14","current":-4.371311,"twenty":-13.716463,"median":-8.19958,"eighty":17.604827,"marketCap":184722859},{"date":"2025-03-21","current":-4.377433,"twenty":-13.63957,"median":-8.126889,"eighty":17.576068,"marketCap":184981575},{"date":"2025-03-28","current":-4.561102,"twenty":-13.619937,"median":-7.567165,"eighty":17.520762,"marketCap":192743040},{"date":"2025-04-04","current":-3.75296,"twenty":-13.617995,"median":-7.116479,"eighty":17.456608,"marketCap":158592595},{"date":"2025-04-11","current":-2.528503,"twenty":-13.600664,"median":-6.847522,"eighty":17.401302,"marketCap":106849497},{"date":"2025-04-17","current":-2.681561,"twenty":-13.574128,"median":-6.436815,"eighty":17.385817,"marketCap":113317384},{"date":"2025-04-25","current":-2.767272,"twenty":-13.55286,"median":-5.742614,"eighty":17.372544,"marketCap":116939401},{"date":"2025-05-02","current":-2.430547,"twenty":-13.541408,"median":-5.640845,"eighty":17.334936,"marketCap":102710049},{"date":"2025-05-09","current":-2.418302,"twenty":-13.513595,"median":-5.553616,"eighty":17.244235,"marketCap":102192618},{"date":"2025-05-16","current":-2.045592,"twenty":-13.477603,"median":-5.430041,"eighty":17.188929,"marketCap":101933903},{"date":"2025-05-23","current":-2.030017,"twenty":-13.462755,"median":-5.321004,"eighty":17.144685,"marketCap":101157756},{"date":"2025-05-30","current":-1.853493,"twenty":-13.455721,"median":-5.117468,"eighty":17.144685,"marketCap":92361429},{"date":"2025-06-06","current":-2.154621,"twenty":-13.448154,"median":-4.770625,"eighty":17.122563,"marketCap":107366928},{"date":"2025-06-13","current":-2.40383,"twenty":-13.399073,"median":-4.628447,"eighty":17.122563,"marketCap":119785271},{"date":"2025-06-20","current":-1.895028,"twenty":-13.379975,"median":-4.585591,"eighty":17.104865,"marketCap":94431153},{"date":"2025-06-27","current":-2.081935,"twenty":-13.328858,"median":-4.536848,"eighty":17.091592,"marketCap":103744911},{"date":"2025-07-03","current":-2.014441,"twenty":-13.312364,"median":-4.445597,"eighty":17.06947,"marketCap":100381610},{"date":"2025-07-11","current":-2.092319,"twenty":-13.309092,"median":-4.377433,"eighty":17.036286,"marketCap":104262342},{"date":"2025-07-18","current":-1.993674,"twenty":-13.304184,"median":-4.325394,"eighty":16.96992,"marketCap":99346748},{"date":"2025-07-25","current":-2.959359,"twenty":-13.281279,"median":-4.150909,"eighty":16.894704,"marketCap":147467829},{"date":"2025-08-01","current":-3.063196,"twenty":-13.22336,"median":-4.01928,"eighty":16.841612,"marketCap":152642139},{"date":"2025-08-08","current":-3.062072,"twenty":-13.164683,"median":-3.75296,"eighty":16.657997,"marketCap":174115524},{"date":"2025-08-15","current":-3.58032,"twenty":-12.764301,"median":-3.489183,"eighty":16.507566,"marketCap":203584157},{"date":"2025-08-22","current":-4.951297,"twenty":-12.507357,"median":-3.639499,"eighty":16.427927,"marketCap":281540625},{"date":"2025-08-29","current":-4.956228,"twenty":-11.906412,"median":-3.948873,"eighty":16.385894,"marketCap":281821044},{"date":"2025-09-05","current":-5.419796,"twenty":-11.370375,"median":-4.039068,"eighty":16.354924,"marketCap":308180426},{"date":"2025-09-12","current":-5.824184,"twenty":-11.101417,"median":-4.150909,"eighty":16.301609,"marketCap":331174779},{"date":"2025-09-19","current":-6.115147,"twenty":-10.938589,"median":-4.325394,"eighty":16.232919,"marketCap":347719498},{"date":"2025-09-26","current":-5.355685,"twenty":-10.838275,"median":-4.374303,"eighty":15.930178,"marketCap":304534979},{"date":"2025-10-03","current":-5.301438,"twenty":-10.774307,"median":-4.411924,"eighty":15.250644,"marketCap":301450371},{"date":"2025-10-10","current":-5.996789,"twenty":-10.666723,"median":-4.53049,"eighty":8.143309,"marketCap":340989443},{"date":"2025-10-17","current":-6.144737,"twenty":-10.617293,"median":-4.573346,"eighty":-1.787038,"marketCap":349402011},{"date":"2025-10-24","current":-5.483906,"twenty":-10.566409,"median":-4.58636,"eighty":-1.820784,"marketCap":311825872},{"date":"2025-10-31","current":-5.197875,"twenty":-10.55914,"median":-4.692731,"eighty":-1.833764,"marketCap":295561573},{"date":"2025-11-07","current":-5.410266,"twenty":-10.548963,"median":-4.832939,"eighty":-1.851935,"marketCap":321299446},{"date":"2025-11-14","current":-5.356212,"twenty":-10.534425,"median":-4.919242,"eighty":-1.870107,"marketCap":318089369},{"date":"2025-11-21","current":-6.004854,"twenty":-10.522794,"median":-4.956228,"eighty":-1.897105,"marketCap":356610284},{"date":"2025-11-28","current":-5.439749,"twenty":-10.511164,"median":-5.1056,"eighty":-1.907489,"marketCap":323050396},{"date":"2025-12-05","current":-5.395524,"twenty":-10.480633,"median":-5.127036,"eighty":-1.940717,"marketCap":320423970},{"date":"2025-12-12","current":-6.422541,"twenty":-10.474818,"median":-5.15474,"eighty":-1.961484,"marketCap":381415418},{"date":"2025-12-19","current":-5.596996,"twenty":-10.473364,"median":-5.194017,"eighty":-1.980175,"marketCap":332388800},{"date":"2025-12-26","current":-6.230896,"twenty":-10.467549,"median":-5.225482,"eighty":-1.988482,"marketCap":370034239},{"date":"2026-01-02","current":-5.616652,"twenty":-10.432657,"median":-5.250562,"eighty":-1.988482,"marketCap":333556100},{"date":"2026-01-09","current":-5.640545,"twenty":-10.418119,"median":-5.238277,"eighty":-1.992636,"marketCap":334975047},{"date":"2026-01-16","current":-7.282885,"twenty":-10.370143,"median":-5.311221,"eighty":-1.993674,"marketCap":432508676},{"date":"2026-01-23","current":-7.76882,"twenty":-10.358512,"median":-5.340862,"eighty":-1.996789,"marketCap":461366940},{"date":"2026-01-30","current":-8.980584,"twenty":-10.345428,"median":-5.356212,"eighty":-2.000423,"marketCap":533329955},{"date":"2026-02-06","current":-8.906771,"twenty":-10.297451,"median":-5.376869,"eighty":-2.009249,"marketCap":528946421},{"date":"2026-02-13","current":-9.152815,"twenty":-10.253836,"median":-5.386426,"eighty":-2.014441,"marketCap":543558201},{"date":"2026-02-20","current":-9.841736,"twenty":-10.233483,"median":-5.400438,"eighty":-2.020671,"marketCap":584471184},{"date":"2026-02-27","current":-9.706412,"twenty":-10.211675,"median":-5.415031,"eighty":-2.032093,"marketCap":576434705},{"date":"2026-03-06","current":-8.494648,"twenty":-10.131715,"median":-5.429659,"eighty":-2.035208,"marketCap":504471690},{"date":"2026-03-13","current":-8.627788,"twenty":-10.022678,"median":-5.439635,"eighty":-2.037285,"marketCap":517477458},{"date":"2026-03-20","current":-7.538421,"twenty":-10.003778,"median":-5.449385,"eighty":-2.042477,"marketCap":452139395},{"date":"2026-03-27","current":-8.497064,"twenty":-9.968886,"median":-5.459248,"eighty":-2.051822,"marketCap":509636891},{"date":"2026-04-02","current":-8.372565,"twenty":-9.928179,"median":-5.466715,"eighty":-2.065321,"marketCap":502169684},{"date":"2026-04-10","current":-7.986617,"twenty":-9.906238,"median":-5.479061,"eighty":-2.081935,"marketCap":479021341},{"date":"2026-04-17","current":-8.27919,"twenty":-9.836054,"median":-5.512918,"eighty":-2.084012,"marketCap":496569278},{"date":"2026-04-24","current":-7.731394,"twenty":-9.810397,"median":-5.553616,"eighty":-2.100626,"marketCap":463713567},{"date":"2026-05-01","current":-7.980392,"twenty":-9.782709,"median":-5.593479,"eighty":-2.134892,"marketCap":478647981},{"date":"2026-05-08","current":-9.346147,"twenty":-9.716345,"median":-5.597332,"eighty":-2.142161,"marketCap":546226206},{"date":"2026-05-15","current":-9.090076,"twenty":-9.706412,"median":-5.616855,"eighty":-2.169158,"marketCap":531260417},{"date":"2026-05-22","current":-9.192428,"twenty":-9.705988,"median":-5.636308,"eighty":-2.233537,"marketCap":537242237},{"date":"2026-05-29","current":-8.51435,"twenty":-9.70429,"median":-5.640545,"eighty":-2.258458,"marketCap":497612677},{"date":"2026-06-05","current":-7.893845,"twenty":-9.687959,"median":-5.659308,"eighty":-2.268842,"marketCap":461347892},{"date":"2026-06-12","current":-7.586791,"twenty":-9.667944,"median":-5.675619,"eighty":-2.28961,"marketCap":443402431},{"date":"2026-06-18","current":-7.7787,"twenty":-9.662129,"median":-5.714931,"eighty":-2.297916,"marketCap":454618344},{"date":"2026-06-26","current":-8.546335,"twenty":-9.628373,"median":-5.735345,"eighty":-2.299993,"marketCap":499481996},{"date":"2026-07-02","current":-9.748963,"twenty":-9.663583,"median":-5.762064,"eighty":-2.315568,"marketCap":569768385},{"date":"2026-07-10","current":-9.883299,"twenty":-9.694491,"median":-5.794595,"eighty":-2.329935,"marketCap":577619524},{"date":"2026-07-17","current":-8.962137,"twenty":-9.694491,"median":-5.82665,"eighty":-2.336264,"marketCap":523783141},{"date":"2026-07-24","current":-9.192428,"twenty":-9.67595,"median":-5.858705,"eighty":-2.342386,"marketCap":537242237},{"date":"2026-07-31","current":-10.230297,"twenty":-9.679953,"median":-5.883363,"eighty":-2.347666,"marketCap":588835437},{"date":"2026-08-07","current":-10.033086,"twenty":-9.712752,"median":-5.989392,"eighty":-2.358877,"marketCap":577484376},{"date":"2026-08-14","current":-10.000405,"twenty":-9.736909,"median":-5.997033,"eighty":-2.370666,"marketCap":575603319},{"date":"2026-08-21","current":-10.471012,"twenty":-9.774333,"median":-6.022053,"eighty":-2.376833,"marketCap":602690534},{"date":"2026-08-28","current":-11.274967,"twenty":-9.837227,"median":-6.092955,"eighty":-2.39137,"marketCap":648964527},{"date":"2026-09-04","current":-11.484125,"twenty":-9.932538,"median":-6.109132,"eighty":-2.409619,"marketCap":661003289},{"date":"2026-09-11","current":-9.582088,"twenty":-9.971533,"median":-6.111778,"eighty":-2.420751,"marketCap":551525795},{"date":"2026-09-18","current":-8.634337,"twenty":-9.933507,"median":-6.142445,"eighty":-2.430547,"marketCap":496975153},{"date":"2026-09-25","current":-8.163729,"twenty":-9.928179,"median":-6.158368,"eighty":-2.432996,"marketCap":469887938},{"date":"2026-10-02","current":-8.49054,"twenty":-9.917056,"median":-6.230896,"eighty":-2.442791,"marketCap":488698504},{"date":"2026-10-09","current":-8.614728,"twenty":-9.893321,"median":-6.563612,"eighty":-2.44524,"marketCap":495846519},{"date":"2026-10-12","current":-8.745452,"twenty":-9.890815,"median":-6.704683,"eighty":-2.447689,"marketCap":503370746}],"updateTime":1791915937922},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CTNM\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2667649050","title":"Contineum price target lowered to $19 from $20 at Baird","url":"https://stock-news.laohu8.com/highlight/detail?id=2667649050","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667649050?lang=en_us&edition=fundamental","pubTime":"2026-09-15 19:00","pubTimestamp":1789470010,"startTime":"0","endTime":"0","summary":"Baird lowered the firm’s price target on Contineum (CTNM) to $19 from $20 and keeps an Outperform rating on the shares. The fim updated its model i...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/contineum-price-target-lowered-to-19-from-20-at-baird-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/contineum-price-target-lowered-to-19-from-20-at-baird-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CTNM","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667649465","title":"Contineum Therapeutics, Inc. : Leerink Partners Cuts Target Price to $22 from $25","url":"https://stock-news.laohu8.com/highlight/detail?id=2667649465","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667649465?lang=en_us&edition=fundamental","pubTime":"2026-09-15 18:56","pubTimestamp":1789469812,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260915:nFWN45709K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CTNM","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667691346","title":"Stocks to Watch: Dave & Buster's, Contineum, Boxlight, Kestra Medical","url":"https://stock-news.laohu8.com/highlight/detail?id=2667691346","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667691346?lang=en_us&edition=fundamental","pubTime":"2026-09-15 07:20","pubTimestamp":1789428000,"startTime":"0","endTime":"0","summary":"Dave & Buster's Entertainment swung to a loss and posted lower sales in its latest quarter. The stock slid 12%, to $7.43, in after-hours trading Monday.Contineum Therapeutics said a trial measuring a treatment for depression failed to meet its primary endpoint. Shares declined 4%, to $14.30, after the bell.Boxlight regained compliance with Nasdaq's listing requirements. The stock rose 6%, to $5.75.Kestra Medical Technologies posted a wider-than-expected loss in its latest quarter. Shares fell 10%, to $21.76.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTNM","KMTS","BK4216","BK4209","BK4565","BK4007","PLAY","BK4082","BK4170","BOXL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667269916","title":"Analyst Maintains Buy on Contineum, Trims Price Target to $23 Following PIPE-307 Setback While PIPE-791 IPF Program Remains Core Value Driver","url":"https://stock-news.laohu8.com/highlight/detail?id=2667269916","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667269916?lang=en_us&edition=fundamental","pubTime":"2026-09-15 06:35","pubTimestamp":1789425321,"startTime":"0","endTime":"0","summary":"Gaurav Maini, an analyst from LifeSci Capital, maintained the Buy rating on Contineum Therapeutics, Inc. Class A. The associated price target was l...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/analyst-maintains-buy-on-contineum-trims-price-target-to-23-following-pipe-307-setback-while-pipe-791-ipf-program-remains-core-value-driver-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/analyst-maintains-buy-on-contineum-trims-price-target-to-23-following-pipe-307-setback-while-pipe-791-ipf-program-remains-core-value-driver-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","CTNM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667991516","title":"Analyst Reaffirms Buy on Contineum, Highlighting PIPE-791 IPF Upside Despite Muscarinic MDD Trial Setback","url":"https://stock-news.laohu8.com/highlight/detail?id=2667991516","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667991516?lang=en_us&edition=fundamental","pubTime":"2026-09-15 06:25","pubTimestamp":1789424719,"startTime":"0","endTime":"0","summary":"William Blair analyst Myles Minter has reiterated their bullish stance on CTNM stock, giving a Buy rating on September 3. Myles Minter has given hi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/analyst-reaffirms-buy-on-contineum-highlighting-pipe-791-ipf-upside-despite-muscarinic-mdd-trial-setback-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/analyst-reaffirms-buy-on-contineum-highlighting-pipe-791-ipf-upside-despite-muscarinic-mdd-trial-setback-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","ABVC","CTNM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667695720","title":"Contineum Therapeutics Says Phase 2 Major Depressive Disorder Study Fails to Meet Primary Efficacy Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2667695720","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667695720?lang=en_us&edition=fundamental","pubTime":"2026-09-15 04:52","pubTimestamp":1789419160,"startTime":"0","endTime":"0","summary":"Contineum Therapeutics  said late Monday the phase 2 MOONLIGHT-1 trial of JNJ-5120/PIPE-307 for the treatment of major depressive disorder did not meet its primary efficacy endpoint.JNJ-5120/PIPE-307 is being developed by Johnson & Johnson  under a global license and development agreement, the company noted.The study evaluated improvement from baseline in the Montgomery-Asberg Depression Rating Scale total score at Day 5 compared with placebo, the company said, adding that the treatment was well tolerated and showed no new safety signals.Johnson & Johnson is continuing to review the trial data, including prespecified exploratory endpoints, to determine next steps for the program, according to a statement.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MEDX","LU0289739343.SGD","LU2347655156.SGD","RXL","LU0124676726.USD","CTNM","LU0234570918.USD","LU2430703251.USD","LU1629891620.HKD","BK4585","JDOC","FHLC","IHE","LU1929549753.HKD","FTXH","LU1551013425.SGD","LU2471134523.USD","PJP","IE00BLSP4452.SGD","LU2471134952.CNY","IE00B1BXHZ80.USD","BK4581","GDOC","LU0820561818.USD","IYH","LU1061106388.HKD","LU0882574055.USD","LU1244550494.USD","LU1066051811.HKD","IE00BKVL7J92.USD","LU0820561909.HKD","XLV","JNJ","LU0426412945.USD","VHT","LU0058720904.USD","BK4534","LU2471134879.HKD","LU0210536198.USD","LU0289739699.SGD","TRUH","LU0943347566.SGD","BMED","SG9999001440.SGD","LU0466842654.USD","LU0162691827.USD","IXJ","LU2129689431.USD","SG9999001176.USD","IE0001KFT4U8.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667695187","title":"Contineum Therapeutics Shares Fall After Drug Trial Missed Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2667695187","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667695187?lang=en_us&edition=fundamental","pubTime":"2026-09-15 04:36","pubTimestamp":1789418160,"startTime":"0","endTime":"0","summary":"Shares of Contineum Therapeutics were trading lower after-hours Monday, following news a Phase 2 trial of an treatment for depression failed to meet its primary efficacy endpoint.Contineum said JNJ-5120/PIPE-307 is being developed by Johnson & Johnson under a global license and development agreement. The Phase 2 Moonlight-1 trial didn't meet its primary efficacy endpoint, although the treatment was well-tolerated with no new safety signals, the company added.Analyses of the data are ongoing, Contineum said.After the bell, shares of Contineum were trading 8.2% lower, at $13.59.  The stock ended the day's regular session flat, at $14.82.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGXZ80539844.SGD","LU1162221912.USD","LU0345769128.USD","IE00BLSP4452.SGD","LU0792757196.USD","IE000BZT7R73.USD","LU0820562030.AUD","LU2213496289.HKD","LU0210528500.USD","LU0203345920.USD","LU1674673691.USD","BK4550","LU0114720955.EUR","LU0162691827.USD","LU0057025933.USD","IHE","LU2430703178.SGD","JNJ","XLV","GDOC","IE00BFTCPJ56.SGD","VHT","LU2456880835.USD","FTXH","TRUH","IYH","BMED","LU2430703251.USD","MEDX","LU1228905540.USD","SG9999001176.USD","FHLC","LU0124676726.USD","LU0994945656.USD","IXJ","IE00BGHQF631.EUR","PJP","IE00BBT3K403.USD","IE00BN8TJ469.HKD","LU1551013342.USD","CTNM","LU0943347566.SGD","LU0345770308.USD","RXL","JDOC","LU0426417589.USD","IE0002141913.USD","IE00B19Z3B42.SGD","IE0009355771.USD","BK4559"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667954476","title":"Contineum Therapeutics Reports Phase 2 MOONLIGHT-1 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2667954476","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667954476?lang=en_us&edition=fundamental","pubTime":"2026-09-15 04:31","pubTimestamp":1789417870,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Contineum Therapeutics, Inc. Class A ( ($CTNM) ). On September 14, 2026, Contineum Therapeutics reported top-li...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/contineum-therapeutics-reports-phase-2-moonlight-1-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/contineum-therapeutics-reports-phase-2-moonlight-1-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","CTNM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667769302","title":"Contineum, J&J's Depression Drug Fails to Meet Mid-Stage Trial Goal","url":"https://stock-news.laohu8.com/highlight/detail?id=2667769302","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667769302?lang=en_us&edition=fundamental","pubTime":"2026-09-15 04:11","pubTimestamp":1789416676,"startTime":"0","endTime":"0","summary":"Contineum, J&J's depression drug fails to meet mid-stage trial goalSept 15 (Reuters)-Contineum TherapeuticsCTNM.Osaid on Monday an experimental depression drug it developed with Johnson & JohnsonJNJ.Nfailed to meet the main goal of a mid-stage study.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260914:nL4N4561IL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IXJ","RXL","LU1674673428.USD","CTNM","IE00B3PB1722.GBP","IE00B3T34201.USD","IE00BDGV0183.EUR","IE00BZ1G4Q59.USD","LU2213496289.HKD","TRUH","LU0820561818.USD","LU2487616109.SGD","FHLC","SGXZ57979304.SGD","LU0345769631.USD","LU2236285917.USD","LU1894683348.USD","LU2023250330.USD","LU1121112475.USD","IE000WAW04H5.SGD","VHT","IYH","MEDX","IE0009355771.USD","LU1043141123.HKD","XLV","LU0912757837.SGD","IE00BN8TJ469.HKD","JDOC","LU2592432038.USD","LU2129689605.HKD","IHE","LU1629891620.HKD","LU1196500208.SGD","BK4559","IE000M9KFDE8.USD","IE00BVYPNV92.GBP","IE00B19Z3581.USD","FTXH","LU0234572021.USD","LU1430594728.SGD","JNJ","BMED","PJP","LU2505996509.AUD","LU1929549753.HKD","LU1074936037.SGD","LU2133065610.SGD","LU1894683264.USD","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667469539","title":"Contineum says MOONLIGHT-1 trial did not achieve its primary endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2667469539","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667469539?lang=en_us&edition=fundamental","pubTime":"2026-09-15 04:10","pubTimestamp":1789416618,"startTime":"0","endTime":"0","summary":"The company states: “Contineum (CTNM) Therapeutics announced that the MOONLIGHT-1 trial did not achieve its primary efficacy endpoint. The trial ev...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/contineum-says-moonlight-1-trial-did-not-achieve-its-primary-endpoint-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/contineum-says-moonlight-1-trial-did-not-achieve-its-primary-endpoint-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","CTNM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667695366","title":"Contineum down 11% atter MOONLIGHT-1 trial did not achieve endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2667695366","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667695366?lang=en_us&edition=fundamental","pubTime":"2026-09-15 04:10","pubTimestamp":1789416607,"startTime":"0","endTime":"0","summary":"16:09 EDT Contineum (CTNM) down 11% atter MOONLIGHT-1 trial did not achieve endpoint Published first on TheFly – the ultimate source for real-time,...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/contineum-down-11-atter-moonlight-1-trial-did-not-achieve-endpoint-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/contineum-down-11-atter-moonlight-1-trial-did-not-achieve-endpoint-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CTNM","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667937696","title":"Contineum Therapeutics, - Jnj-5120/Pipe-307 Well-Tolerated with no New Safety Signals","url":"https://stock-news.laohu8.com/highlight/detail?id=2667937696","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667937696?lang=en_us&edition=fundamental","pubTime":"2026-09-15 04:05","pubTimestamp":1789416300,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260914:nTUABTMJR3:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CTNM","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667752693","title":"Contineum Therapeutics, - Analyses of Data Including Exploratory Endpoints are Ongoing","url":"https://stock-news.laohu8.com/highlight/detail?id=2667752693","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667752693?lang=en_us&edition=fundamental","pubTime":"2026-09-15 04:05","pubTimestamp":1789416300,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260914:nTUABTMJR3:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CTNM","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667693793","title":"Contineum Therapeutics Reports Phase 2 Results for Jnj-5120/Pipe-307 for the Treatment of Major Depressive Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2667693793","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667693793?lang=en_us&edition=fundamental","pubTime":"2026-09-15 04:05","pubTimestamp":1789416300,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260914:nTUABTMJR3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CTNM","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667693759","title":"Contineum Therapeutics, - Phase 2 Moonlight-1 Trial Did not Meet Primary Efficacy Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2667693759","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667693759?lang=en_us&edition=fundamental","pubTime":"2026-09-15 04:05","pubTimestamp":1789416300,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260914:nTUABTMJR3:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CTNM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667693701","title":"Contineum Therapeutics, - Johnson & Johnson Continues to Evaluate Trial Data for Jnj-5120/Pipe-307","url":"https://stock-news.laohu8.com/highlight/detail?id=2667693701","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667693701?lang=en_us&edition=fundamental","pubTime":"2026-09-15 04:05","pubTimestamp":1789416300,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260914:nTUABTMJR3:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TRUH","IYH","SG9999001440.SGD","JDOC","LU0098860793.USD","LU0053666078.USD","VHT","LU0072461881.USD","LU0345769128.USD","LU1066051498.USD","RXL","LU1935042991.SGD","LU1989771016.USD","LU1145028129.USD","FHLC","LU1674673691.USD","LU1674673428.USD","LU0994945656.USD","LU1929549753.HKD","BK4533","LU0289961442.SGD","LU0203347892.USD","CTNM","LU0792757196.USD","GDOC","IE0001KFT4U8.USD","LU0234572021.USD","LU0345770993.USD","LU2468319806.SGD","FTXH","IHE","IE00B42XCP33.USD","LU1043141396.HKD","LU2456880835.USD","MEDX","IE00BGHQF631.EUR","LU0432979614.USD","LU0882574055.USD","LU0210536198.USD","LU0820562030.AUD","XLV","JNJ","LU1043141123.HKD","BMED","IXJ","LU0545562505.USD","IE0002141913.USD","LU1496350502.SGD","PJP","IE000BZT7R73.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666370027","title":"Contineum Therapeutics CEO Carmine N. Stengone Disposes of 2,500 Common Shares for $41,141.5","url":"https://stock-news.laohu8.com/highlight/detail?id=2666370027","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666370027?lang=en_us&edition=fundamental","pubTime":"2026-09-09 06:09","pubTimestamp":1788905361,"startTime":"0","endTime":"0","summary":"Contineum Therapeutics CEO Carmine N. Stengone disposes of 2,500 common shares for $41,141.5Contineum Therapeutics CEO and President Carmine N. Stengone sold 2,500 Class A common shares at USD 16.46 o","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nNDL9hqqxt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Contineum Therapeutics CEO Carmine N. Stengone Disposes of 2,500 Common Shares for $41,141.5","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CTNM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664587900","title":"Contineum Therapeutics, Inc. Class A (CTNM) Receives a Buy from RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2664587900","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664587900?lang=en_us&edition=fundamental","pubTime":"2026-09-03 19:35","pubTimestamp":1788435326,"startTime":"0","endTime":"0","summary":"RBC Capital analyst Brian Abrahams maintained a Buy rating on Contineum Therapeutics, Inc. Class A today and set a price target of $23.00. Accordin...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/contineum-therapeutics-inc-class-a-ctnm-receives-a-buy-from-rbc-capital-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/contineum-therapeutics-inc-class-a-ctnm-receives-a-buy-from-rbc-capital-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4207","LU0310800379.SGD","LU0708994859.HKD","LU0128525929.USD","LU1267930573.SGD","CTNM","GSIB","BK4007","LU0029864427.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662731791","title":"Contineum Therapeutics to Present at Morgan Stanley Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2662731791","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662731791?lang=en_us&edition=fundamental","pubTime":"2026-08-26 17:29","pubTimestamp":1787736547,"startTime":"0","endTime":"0","summary":"Contineum Therapeutics to present at Morgan Stanley Global Healthcare ConferenceContineum will present at the 2026 Morgan Stanley Global Healthcare Conference on Sept. 15.Management is scheduled for a","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nNDL8WJ3Xp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CTNM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660435025","title":"Contineum, Disc Medicine, Recursion Advance Pipelines Ahead of Catalysts, Morgan Stanley Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2660435025","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660435025?lang=en_us&edition=fundamental","pubTime":"2026-08-17 23:01","pubTimestamp":1786978897,"startTime":"0","endTime":"0","summary":"Contineum Therapeutics , Disc Medicine , and Recursion Pharmaceuticals  are making meaningful pipeline progress, with key clinical and regulatory catalysts ahead in 2026, Morgan Stanley said in a note Monday.Contineum had a solid Q2, with the company advancing PIPE-791 toward a potentially large idiopathic pulmonary fibrosis opportunity, backed by strong trial progress, better tolerability, additional chronic-pain potential, and enough cash to fund operations through mid-2029, the investment firm said.Morgan Stanley said Disc Medicine is seeing \"very strong\" demand for bitopertin, with its expanded access program launched ahead of a phase 3 trial readout expected in Q4. Management says demand is currently limited by operational bandwidth, not patient interest, according to the note.Recursion Pharmaceuticals is showing growing validation of its artificial intelligence drug-discovery platform, the firm said. The company cut its 2026 cash spending forecast to about $375 million from rough","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4548","IRON","BK4139","RXRX","BK4007","BK4539","LU0053671581.USD","BK4609","BK4611","CTNM"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":2,"totalSize":79,"code":"91000000","status":"200"}]}}